Your browser doesn't support javascript.
loading
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Baertsch, Marc-Andrea; Mai, Elias K; Hielscher, Thomas; Bertsch, Uta; Salwender, Hans J; Munder, Markus; Fuhrmann, Stephan; Dührsen, Ulrich; Brossart, Peter; Neben, Kai; Schlenzka, Jana; Kunz, Christina; Raab, Marc S; Hillengaß, Jens; Jauch, Anna; Seckinger, Anja; Hose, Dirk; Luntz, Steffen; Sonneveld, Pieter; Lokhorst, Henk; Martin, Hans; Goerner, Martin; Hoffmann, Martin; Lindemann, Hans-Walter; Bernhard, Helga; Blau, Igor W; Scheid, Christof; Besemer, Britta; Weisel, Katja C; Hänel, Mathias; Dürig, Jan; Goldschmidt, Hartmut.
Afiliação
  • Baertsch MA; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Mai EK; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Hielscher T; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bertsch U; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Salwender HJ; Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg, Germany.
  • Munder M; Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany.
  • Fuhrmann S; Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.
  • Dührsen U; Department of Hematology and Stem Cell Transplantation, Helios Hospital Berlin Buch, Berlin, Germany.
  • Brossart P; Department of Hematology, University Clinic Essen, Essen, Germany.
  • Neben K; University Hospital Bonn, Bonn, Germany.
  • Schlenzka J; Department of Hematology and Oncology, Klinikum Baden Baden, Baden Baden, Germany.
  • Kunz C; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Raab MS; Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg, Germany.
  • Hillengaß J; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jauch A; Institute of Child Nutrition, Max Rubner Institute, Federal Research Institute of Nutrition and Food, Karlsruhe, Germany.
  • Seckinger A; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Hose D; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Luntz S; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Sonneveld P; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
  • Lokhorst H; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Martin H; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Goerner M; Department of Hematology and Immunology, Myeloma Center Brussels, Jette, Belgium.
  • Hoffmann M; Coordination Centre for Clinical Trials (KKS) Heidelberg, Heidelberg, Germany.
  • Lindemann HW; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Bernhard H; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
  • Blau IW; Department of Medicine, Hematology/Oncology, Goethe-University of Frankfurt, Frankfurt, Germany.
  • Scheid C; Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld, Bielefeld, Germany.
  • Besemer B; Medical Clinic A, Klinikum Ludwigshafen, Ludwigshafen, Germany.
  • Weisel KC; Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany.
  • Hänel M; Internal Medicine V, Klinikum Darmstadt, Darmstadt, Germany.
  • Dürig J; Medical Clinic, Charité University Medicine Berlin, Berlin, Germany.
  • Goldschmidt H; Department of Internal Medicine I, University Hospital Köln, Köln, Germany.
Blood Cancer J ; 11(1): 1, 2021 01 07.
Article em En | MEDLINE | ID: mdl-33414374
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Bortezomib / Lenalidomida / Fatores Imunológicos / Mieloma Múltiplo / Antineoplásicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Bortezomib / Lenalidomida / Fatores Imunológicos / Mieloma Múltiplo / Antineoplásicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha